Trials / Unknown
UnknownNCT05638256
68Ga-labeled NY104 PET Imaging in Patients
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Affiliated Hospital of Jiangnan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY104 PET Imaging in patients with Renal Cell Carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-NY104 | Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104 |
Timeline
- Start date
- 2022-10-10
- Primary completion
- 2023-10-01
- Completion
- 2023-10-01
- First posted
- 2022-12-06
- Last updated
- 2022-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05638256. Inclusion in this directory is not an endorsement.